Bhavuk Dhamija

Bhavuk Dhamija

Auto-generated profile, based on publicly available information

Bhavuk Dhamija

Department of Biosciences and Bioengineering, IIT Bombay, Mumbai, India

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2023 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
BDBhavuk Dhamija
Bhavuk Dhamija
SMSoumitra Marathe
Soumitra Marathe
VSVinanti Sawant
Vinanti Sawant
MBMoumita Basu
Moumita Basu
DADiksha Attrish
Diksha Attrish
RPRahul Purwar
Rahul Purwar
Immune cell–derived IL-17A is one of the key pathogenic cytokines in psoriasis, an immunometabolic disorder. Although IL-17A is an established regulator of cutaneous immune cell biology, its functional and metabolic effects on nonimmune cells of the skin, particularly keratinocytes, have not been comprehensively explored. Using multiomics profiling and systems biology–based approaches, we systematically uncover significant roles for IL-17A in the metabolic reprogramming of human primary keratinocytes (HPKs). High-throughput liquid chromatography–tandem mass spectrometry and nuclear magnetic resonance spectroscopy revealed IL-17A–dependent regulation of multiple HPK proteins and metabolites of carbohydrate and lipid metabolism. Systems-level MitoCore modeling using flux-balance analysis identified IL-17A–mediated increases in HPK glycolysis, glutaminolysis, and lipid uptake, which were validated using biochemical cell-based assays and stable isotope-resolved metabolomics. IL-17A treatment triggered downstream mitochondrial reactive oxygen species and HIF1α expression and resultant HPK proliferation, consistent with the observed elevation of these downstream effectors in the epidermis of patients with psoriasis. Pharmacological inhibition of HIF1α or reactive oxygen species reversed IL-17A–mediated glycolysis, glutaminolysis, lipid uptake, and HPK hyperproliferation. These results identify keratinocytes as important target cells of IL-17A and reveal its involvement in multiple downstream metabolic reprogramming pathways in human skin.

1 August 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
SMSoumitra Marathe
Soumitra Marathe
BDBhavuk Dhamija
Bhavuk Dhamija
SKSushant Kumar
Sushant Kumar
NJNikita Jain
Nikita Jain
SGSarbari Ghosh
Sarbari Ghosh
RPRahul Purwar
Rahul Purwar

14 May 2025 in Molecular Cancer Research
Verified
Journal Article
Closed access
DMDitipriya Mukherjee
Ditipriya Mukherjee
SMSoumitra Marathe
Soumitra Marathe
DADiksha Attrish
Diksha Attrish
VSVinanti Sawant
Vinanti Sawant
BDBhavuk Dhamija
Bhavuk Dhamija
RPRahul Purwar
Rahul Purwar
Cutaneous T-cell lymphoma (CTCL) is a multistage disease characterized by rapid dissemination of malignant T lymphocytes from skin lesions to visceral organs and bone marrow. The cytokine IL-9 and its receptor (IL-9R) are aberrantly overexpressed in CTCL lesions and function to enhance tumor cell survival. In this study, we uncovered a critical new role for IL-9 as a potent inducer of migration of malignant T cells. Stimulation of IL-9R–expressing T-cell lymphoma cells with IL-9 induced a pseudohypoxic cellular state by elevating downstream levels of the promigratory and oxygen-sensing transcription factor hypoxia-inducible factor (HIF)-1α. High-throughput quantitative proteomic analyses of pseudohypoxic malignant T cells identified the actin-modulating protein cofilin-1 (CFL-1) as a promigratory CTCL-intrinsic target downstream of IL-9–HIF-1α signaling. Consistently, multicolor immunofluorescence staining revealed marked coexpression of CFL-1 with HIF-1α in both IL-9–treated human lymphoma cell lines and in patient CTCL skin biopsies compared with normal controls. Genetic knockdown of IL9R or HIF1A in human T-cell lymphoma lines by RNAi significantly reduced both HIF-1α and CFL-1 coexpression and reversed IL-9–induced migration. Finally, pharmacologic antagonism of HIF-1α activity using the FDA-designated orphan drug echinomycin significantly abrogated IL-9–triggered migration of both malignant T-cell lines and patient-derived T-cell lymphoma cells from CTCL biospecimens. Implications: Our results uncover a CTCL-intrinsic IL-9–HIF-1α–CFL-1 axis as a critical promoter of malignant T-cell migration. They further identify HIF-1α and CFL-1 as promising therapeutic targets to mitigate IL-9–induced CTCL dissemination.

4 September 2025
Verified
Other
Open access
DMDitipriya Mukherjee
Ditipriya Mukherjee
SMSoumitra Marathe
Soumitra Marathe
DADiksha Attrish
Diksha Attrish
VSVinanti Sawant
Vinanti Sawant
BDBhavuk Dhamija
Bhavuk Dhamija
RPRahul Purwar
Rahul Purwar
Western blotting data showing differential expression of HIF-1α due to IL9R knockdown or overexpression in malignant T-cells.

4 September 2025
Verified
Other
Open access
DMDitipriya Mukherjee
Ditipriya Mukherjee
SMSoumitra Marathe
Soumitra Marathe
DADiksha Attrish
Diksha Attrish
VSVinanti Sawant
Vinanti Sawant
BDBhavuk Dhamija
Bhavuk Dhamija
RPRahul Purwar
Rahul Purwar
Cutaneous T-cell lymphoma (CTCL) is a multistage disease characterized by rapid dissemination of malignant T lymphocytes from skin lesions to visceral organs and bone marrow. The cytokine IL-9 and its receptor (IL-9R) are aberrantly overexpressed in CTCL lesions and function to enhance tumor cell survival. In this study, we uncovered a critical new role for IL-9 as a potent inducer of migration of malignant T cells. Stimulation of IL-9R–expressing T-cell lymphoma cells with IL-9 induced a pseudohypoxic cellular state by elevating downstream levels of the promigratory and oxygen-sensing transcription factor hypoxia-inducible factor (HIF)-1α. High-throughput quantitative proteomic analyses of pseudohypoxic malignant T cells identified the actin-modulating protein cofilin-1 (CFL-1) as a promigratory CTCL-intrinsic target downstream of IL-9–HIF-1α signaling. Consistently, multicolor immunofluorescence staining revealed marked coexpression of CFL-1 with HIF-1α in both IL-9–treated human lymphoma cell lines and in patient CTCL skin biopsies compared with normal controls. Genetic knockdown of IL9R or HIF1A in human T-cell lymphoma lines by RNAi significantly reduced both HIF-1α and CFL-1 coexpression and reversed IL-9–induced migration. Finally, pharmacologic antagonism of HIF-1α activity using the FDA-designated orphan drug echinomycin significantly abrogated IL-9–triggered migration of both malignant T-cell lines and patient-derived T-cell lymphoma cells from CTCL biospecimens.Implications:Our results uncover a CTCL-intrinsic IL-9–HIF-1α–CFL-1 axis as a critical promoter of malignant T-cell migration. They further identify HIF-1α and CFL-1 as promising therapeutic targets to mitigate IL-9–induced CTCL dissemination.

4 September 2025
Verified
Other
Open access
DMDitipriya Mukherjee
Ditipriya Mukherjee
SMSoumitra Marathe
Soumitra Marathe
DADiksha Attrish
Diksha Attrish
VSVinanti Sawant
Vinanti Sawant
BDBhavuk Dhamija
Bhavuk Dhamija
RPRahul Purwar
Rahul Purwar
Quadruple Immunofluorescence staining of healthy unactivated T-cells showing IL-9R, IL-2RG, CD3 and DAPI levels and STRING network analysis showing HIF-1α pathway associated proteins enriched by CoCl2 treatment in Jurkat cells.